Efficacy and Safety of Omalizumab in Adults (18-70 Years) With Moderate to Severe Chronic Urticaria

NCT00481676 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

49

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Urticaria

Interventions

DRUG: Omalizumab 75-375 mg
DRUG: Placebo to omalizumab
DRUG: Loratadine
DRUG: Clemastine

Sponsor

Novartis